Sarah Stevenson1, Wen Tang2, Yeoungjee Cho3, David W Mudge1, Carmel M Hawley1, Sunil V Badve1, David W Johnson1. 1. Department of Nephrology, University of Queensland at Princess Alexandra Hospital, Brisbane, Australia. 2. Department of Nephrology, University of Queensland at Princess Alexandra Hospital, Brisbane, Australia Division of Nephrology, Peking University Third Hospital, Beijing, China. 3. Division of Nephrology, Peking University Third Hospital, Beijing, China.
Abstract
BACKGROUND: There is limited available evidence regarding the role of monitoring serum vancomycin concentrations during treatment of peritoneal dialysis (PD)-associated peritonitis. METHODS: A total of 150 PD patients experiencing 256 episodes of either gram-positive or culture-negative peritonitis were included to investigate the relationship between measured serum vancomycin within the first week and clinical outcomes of cure, relapse, repeat or recurrence of peritonitis, catheter removal, temporary or permanent transfer to hemodialysis, hospitalization and death. RESULTS: Vancomycin was used as an initial empiric antibiotic in 54 gram-positive or culture-negative peritonitis episodes among 34 patients. The median number of serum vancomycin level measurements in the first week was 3 (interquartile range; IQR 1 - 4). The mean day-2 vancomycin level, measured in 34 (63%) episodes, was 17.5 ± 5.2 mg/L. Hospitalized patients were more likely to have serum vancomycin levels measured on day 2 and ≥ 3 measurements in the first week. The peritonitis cure rates were similar between patients with < 3 and ≥ 3 measurements in the first week (77% vs 57%, p = 0.12) and if day-2 vancomycin levels were measured or not (68% vs 65%, p = 0.84). The average day-2 (18.0 ± 5.9 vs 16.6 ± 3.2, p = 0.5), first-week average (18.6 ± 5.1 vs 18.6 ± 4.3, p = 0.9) and nadir (14.5 ± 4.1 vs 13.6 ± 4.2, p = 0.5) vancomycin levels were comparable in patients who did or did not achieve peritonitis cure. Similar results were observed for all other clinical outcomes. CONCLUSION: The clinical outcomes of gram-positive and culture-negative peritonitis episodes are not associated with either the frequency or levels of serum vancomycin measurements in the first week of treatment when vancomycin is dosed according to International Society for Peritoneal Dialysis (ISPD) Guidelines.
BACKGROUND: There is limited available evidence regarding the role of monitoring serum vancomycin concentrations during treatment of peritoneal dialysis (PD)-associated peritonitis. METHODS: A total of 150 PDpatients experiencing 256 episodes of either gram-positive or culture-negative peritonitis were included to investigate the relationship between measured serum vancomycin within the first week and clinical outcomes of cure, relapse, repeat or recurrence of peritonitis, catheter removal, temporary or permanent transfer to hemodialysis, hospitalization and death. RESULTS:Vancomycin was used as an initial empiric antibiotic in 54 gram-positive or culture-negative peritonitis episodes among 34 patients. The median number of serum vancomycin level measurements in the first week was 3 (interquartile range; IQR 1 - 4). The mean day-2 vancomycin level, measured in 34 (63%) episodes, was 17.5 ± 5.2 mg/L. Hospitalized patients were more likely to have serum vancomycin levels measured on day 2 and ≥ 3 measurements in the first week. The peritonitis cure rates were similar between patients with < 3 and ≥ 3 measurements in the first week (77% vs 57%, p = 0.12) and if day-2 vancomycin levels were measured or not (68% vs 65%, p = 0.84). The average day-2 (18.0 ± 5.9 vs 16.6 ± 3.2, p = 0.5), first-week average (18.6 ± 5.1 vs 18.6 ± 4.3, p = 0.9) and nadir (14.5 ± 4.1 vs 13.6 ± 4.2, p = 0.5) vancomycin levels were comparable in patients who did or did not achieve peritonitis cure. Similar results were observed for all other clinical outcomes. CONCLUSION: The clinical outcomes of gram-positive and culture-negative peritonitis episodes are not associated with either the frequency or levels of serum vancomycin measurements in the first week of treatment when vancomycin is dosed according to International Society for Peritoneal Dialysis (ISPD) Guidelines.
Authors: Philip Kam-Tao Li; Cheuk Chun Szeto; Beth Piraino; Judith Bernardini; Ana E Figueiredo; Amit Gupta; David W Johnson; Ed J Kuijper; Wai-Choong Lye; William Salzer; Franz Schaefer; Dirk G Struijk Journal: Perit Dial Int Date: 2010 Jul-Aug Impact factor: 1.756
Authors: Michael Rybak; Ben Lomaestro; John C Rotschafer; Robert Moellering; William Craig; Marianne Billeter; Joseph R Dalovisio; Donald P Levine Journal: Am J Health Syst Pharm Date: 2009-01-01 Impact factor: 2.637
Authors: Neil Boudville; Anna Kemp; Philip Clayton; Wai Lim; Sunil V Badve; Carmel M Hawley; Stephen P McDonald; Kathryn J Wiggins; Kym M Bannister; Fiona G Brown; David W Johnson Journal: J Am Soc Nephrol Date: 2012-05-24 Impact factor: 10.121
Authors: Michael Burke; Carmel M Hawley; Sunil V Badve; Stephen P McDonald; Fiona G Brown; Neil Boudville; Kathryn J Wiggins; Kym M Bannister; David W Johnson Journal: Am J Kidney Dis Date: 2011-05-20 Impact factor: 8.860
Authors: Joanna R Ghali; Kym M Bannister; Fiona G Brown; Johan B Rosman; Kathryn J Wiggins; David W Johnson; Stephen P McDonald Journal: Perit Dial Int Date: 2011-06-30 Impact factor: 1.756
Authors: Thulasi Thirugnanasambathan; Carmel M Hawley; Sunil V Badve; Stephen P McDonald; Fiona G Brown; Neil Boudville; Kathryn J Wiggins; Kym M Bannister; Philip Clayton; David W Johnson Journal: Am J Kidney Dis Date: 2011-08-16 Impact factor: 8.860
Authors: Yeoungjee Cho; Sunil V Badve; Carmel M Hawley; Stephen P McDonald; Fiona G Brown; Neil Boudville; Kathryn J Wiggins; Kym M Bannister; Philip Clayton; David W Johnson Journal: Perit Dial Int Date: 2012-09-01 Impact factor: 1.756
Authors: Philip Kam-Tao Li; Cheuk Chun Szeto; Beth Piraino; Javier de Arteaga; Stanley Fan; Ana E Figueiredo; Douglas N Fish; Eric Goffin; Yong-Lim Kim; William Salzer; Dirk G Struijk; Isaac Teitelbaum; David W Johnson Journal: Perit Dial Int Date: 2016-06-09 Impact factor: 1.756